Rapid M&A Pushes Pharma Debt Higher And Credit Ratings Lower
This article was originally published in The Pink Sheet Daily
Executive Summary
While the industry is expected to grow, the recent emphasis on major M&A has put companies in the precarious position of retaining debt and having little time to de-lever their balance sheets before moving on to the next deal.